D. Boral Capital Acted as Exclusive Placement Agent to Humacyte, Inc. (Nasdaq: HUMA) in Connection with its $60,000,000 Registered Direct Offering
Transaction Information On October 7, 2025, Humacyte, Inc. (the “Company”), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human